Daiichi Sankyo is a global pharmaceutical corporation founded in Japan. The company offers unique goods and services in over 20 countries worldwide. With over 100 years of scientific experience, the company depends on a rich tradition of invention as well as a healthy pipeline of promising new medications to assist patients.

They generate revolutionary new and generic medicines, as well as new ways of drug research and delivery, thanks to the great knowledge and commitment of 15,000 employees globally. They share a passion for innovation as well as compassion for the patients who require our medicines all around the world.

In accordance with their purpose, they have selected "Core Values and Core Behaviors" as the foundation for a cooperative attitude and accurate value judgments, as well as the criterion for our company activities and decision-making. Furthermore, they have formed the Daiichi Sankyo Group Corporate Conduct Charter in order to conduct with the highest ethical standards and a social conscience befitting a company involved in a business that touches human lives.

Founded: Tokyo, Japan (2005) (by merger)

Headquarters: Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan

Key people: Sunao Manabe (Representative Director and President), Ken Keller (President and CEO, Daiichi Sankyo, Inc.)

Website: https://www.daiichisankyo.com/

Takeda is a patient-focused, values-based, R&D-driven multinational biopharmaceutical business dedicated to providing people across the world with Better Health and a Brighter Future. Their commitment for potentially life-changing medicines for patients is profoundly founded in their remarkable history in Japan, which dates back to 1781.

It is Asia's largest pharmaceutical firm and one among the top 20 pharmaceutical companies in the world by revenue (top 10 after its merger with Shire). During the 2018 fiscal year, the corporation had around 49,578 people globally and sales of US$19.299 billion.

Oncology, rare illnesses, neuroscience, gastroenterology, plasma-derived medicines, and vaccines are the primary areas of focus for the organization.

Takeda's Global Headquarters in Nihonbashi, Tokyo, which opened in July 2018, serves as the headquarters for the company's global activities. Kashiwa Sato, one of the world's premier creative directors, created the interior of the building, which represents the essence of Takeda's principles and its basic commitment to always putting patients first.

Takeda Oncology Company was named one of the 100 greatest companies to work for in the United States by Fortune Magazine in January 2012. Christophe Weber was named CEO and President of Takeda in 2015.

Founded: Doshomachi, Osaka, Japan (12 June 1781)

Founder: Chobei Takeda I

Headquarters: Nihonbashi, Chuo, Tokyo, Japan

Key people: Yasuchika Hasegawa, Christophe Weber

Website: https://www.takeda.com/

Chugai Pharmaceutical Co., Ltd. is a Japanese medicine manufacturer. It is a subsidiary of Hoffmann-La Roche, which owned 62% of the firm as of June 30, 2014. Tokyo is the company's headquarters. The current representative director and chairman is Osamu Nagayama. Tatsuro Kosaka is the current president and CEO of the company.

Chugai has built a global reputation for its proprietary antibody engineering technology, as well as its excellent drug discovery skills, which are supported by a research infrastructure that includes small and mid-size compounds. Chugai also focuses on the creation of novel medications using its patented drug discovery technique in order to gain a better understanding of disease biology. Chugai is the market leader in the Japanese therapeutic antibody market. Chugai is always coming up with new R&D ideas. As a result, the Group's drug discovery capabilities have been highly regarded around the world, with six medications developed by Chugai gaining nine Breakthrough Therapy designations from the United States Food and Drug Administration (FDA).

Under the strategic agreement with Roche, one of the world's leading pharmaceutical corporations, Chugai retains management autonomy. Chugai uses Roche's robust research infrastructure and worldwide development and sales platform to provide breakthrough in-house products to the rest of the globe, in addition to efficiently in-licensing the Roche Group's promising pharmaceuticals for sale in Japan. Since the inception of the strategic agreement, Chugai's product range and development pipeline have expanded as a result of in-licensing Roche goods, and Chugai has gained the No. 1 share of the Japanese cancer market. Chugai may focus its spending on highly inventive proprietary technology and medication research now that it has a steady revenue basis.

Chugai has one of the richest development pipelines in Japan, with projects created in-house and in-licensed from Roche, as well as the technology and systems for efficient and stable production of the ensuing new pharmaceuticals. This supports their ongoing provision of novel medications.

As a pioneer of PHC in Japan, Chugai has contributed to the advancement of this healthcare method, in which treatment plans are tailored to each patient's genetic profile and other criteria. Today, Chugai's efforts include delivering PHC that employs genomic analysis technology as well as contributing to the advancement of cancer genomic medicine in order to usher in the next generation of PHC that delivers more advanced treatments that are tailored to each patient.

Chugai has developed a system for providing solutions that can be precisely tailored to the unique demands of different locations, underpinned by industry-leading safety management and a high degree of expertise in each disease area. Chugai's initiatives to promote multidisciplinary team care and regional healthcare coordination include disseminating information, hosting study sessions, and collaborating with the government on awareness-raising activities. Healthcare providers strongly endorse these approaches.

Founded: March 8, 1943

Headquarters: Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo

Key people: Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO

Website: https://www.chugai-pharm.co.jp/

Samsung Biologics is a South Korean biotechnology firm based in Songdo, Incheon, South Korea. Samsung Group's biotech branch provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.

For COVID-19 therapies, the business has collaborated with GlaxoSmithKline, Eli Lilly, and AstraZeneca. During the COVID-19 pandemic, Samsung Biologics collaborated with Moderna to fill-finish, packaging and labeling its mRNA vaccine, Spikevax, and Greenlight Biosciences on manufacturing of mRNA vaccine medicinal substance candidates.

Samsung Biologics is a fully integrated contract development and manufacturing organization that provides cutting-edge contract development and manufacturing services. Samsung Biologics is an award-winning partner of choice, with proven regulatory approvals, the largest capacity, and the fastest throughput. It is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

Samsung Biologics is a dependable partner in the clinical and commercial manufacture, aseptic fill/finish, and analytical testing. From the start of their collaboration, you will have a dedicated project management team to walk you through the whole product development and manufacturing process. They are committed to operational excellence in cGMP production and quality assurance to provide value to their clients.

Founded: 2011
Headquarters: Songdo, Incheon, South Korea
Key people: John Rim, President and CEO

Website: https://samsungbiologics.com/

Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical firm that makes and distributes drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and other related items. It is China's largest publicly traded pharmaceutical corporation.

Jiangsu Hengrui Pharmaceuticals, formerly known as Lianyungang Pharmaceutical Factory, was founded in 1970. Its current headquarters are in Lianyungang, Jiangsu, and it was founded in 1977. In 2000, the firm went public on the Shanghai Stock Exchange, and it now has offices in China, the United States, Germany, Switzerland, Japan, and Australia.

Jiangsu Hengrui Pharmaceuticals will open research and development offices in Princeton, New Jersey, and Basel, Switzerland in 2020. The discovery research and development units are also housed at Hengrui Europe Therapeutics AG in Switzerland. Their primary interests are protein engineering and the mRNA technology platform.

Jiangsu Hengrui Pharmaceuticals has been conducting clinical trials on anti-cancer medications such as:

• An anti-PD-1 immune checkpoint inhibitor camrelizumab for hepatocellular carcinoma;
• A nonsteroidal antiandrogen rezvilutamide for prostate cancer;
• A PARP inhibitor fluzoparib for solid cancers, especially prostate cancer;
• A VEGFR2 inhibitor apatinib as a combination therapy.

Trials were also conducted in the fields of metabolic illnesses (for example, type 2 diabetes), autoimmune diseases (in psoriasis, the interleukin-17 receptor blocker vanucizumab), HIV treatment, and analgesia.

Founded: 1997
Headquarters: Lianyungang, Jiangsu, China
Key people: Sun Piaoyang (chairman)

Website: https://www.hrs.com.cn/

Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. merged to establish Astellas Pharma Inc. on April 1, 2005. The corporation announced management changes effective April 1, 2020 on February 5, 2020. Astellas is a subsidiary of the Mitsubishi UFJ Financial Group (MUFJ).

Astellas is advocating the Focus Area Approach, which focuses on Biology and Modality to discover the potential for the continued development of novel medications to address diseases with significant unmet medical needs.

Furthermore, Astellas is expanding beyond its basic Rx emphasis to develop Rx+® healthcare solutions that combine their expertise and knowledge with cutting-edge technology from external partners in other disciplines.

As a result of these initiatives, Astellas is at the vanguard of healthcare reform, transforming groundbreaking science into VALUE for patients.

Founded: 1 April 2005

Headquarters: 2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan

Key people: Naoki Okamura, Kenji Yasukawa

Website: https://www.astellas.com/en/

Sun Pharma is one of the largest pharmaceutical companies in India and operates globally. Sun Pharma utilizes biotechnology in certain aspects of its operations, primarily in the development and manufacturing of biologics. Biologics are a class of drugs that are derived from living organisms, such as proteins, antibodies, or nucleic acids. They are typically produced using biotechnological processes.

Sun Pharma has invested in building biologics capabilities and has a dedicated division called Sun Pharma Advanced Research Company (SPARC) that focuses on the research and development of innovative biologic drugs. SPARC is involved in developing novel drug delivery platforms, including biologics, peptides, and specialty generics.

Furthermore, Sun Pharma has collaborations and partnerships with other biotechnology companies and research institutions to leverage their expertise in biotech research and development. These collaborations can involve various aspects of biotechnology, such as genetic engineering, protein expression, and bioprocessing.

By incorporating biotechnology into its operations, Sun Pharma aims to expand its product portfolio to include biologics and leverage the potential of biotechnology in developing innovative therapies for various diseases.

Founded: 1983; 40 years ago
Founder: Dilip Shanghvi
Headquarters: Mumbai, India

Key people: Dilip Shanghvi (MD)

Website: https://sunpharma.com/

WuXi AppTec is a multinational pharmaceutical, biopharmaceutical, and medical device manufacturer. Small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics are the company's five core operations.

WuXi AppTec, as a global firm with facilities in Asia, Europe, and North America, offers a diverse range of R&D and manufacturing services to the pharmaceutical and healthcare industries worldwide, enabling them to accelerate discoveries and deliver revolutionary medicines to patients. WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing, and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development, and Manufacturing Organization), assisting customers in increasing the productivity of advancing healthcare products through cost-effective and efficient solutions.

In 2022, WuXi AppTec achieved an AA ESG rating from MSCI, and its open-access platform is enabling over 6,000 clients from over 30 countries to enhance the health of those in need - and to realize the ambition that "every drug can be made and every disease can be treated."

Founded: 2000
Headquarters: Shanghai, China

Key people: Dr. Ge Li

Website: https://www.wuxiapptec.com

BeiGene is a global biotechnology firm that focuses on creating cancer-treatment medications. The company, founded in 2010 by Xiaodong Wang and CEO John V. Oyler, has offices in Asia, North America, Australia, and Europe. BeiGene has created various medications, including the checkpoint inhibitor tislelizumab and the zanubrutinib.

From the start, their R&D team has been focused on developing a pipeline of potentially first-in-class and best-in-class compounds. They are collaborating with one of the world's largest oncology research teams and a worldwide clinical development organization that handles hundreds of clinical trials to achieve this goal. Their clinical trial outcomes, regulatory approvals, and collaborations attest to the strength and quality of their work.

Every day, cancer patients throughout the world face unmet medical needs: some struggle to find treatments that are sufficiently effective against their disease; others discover a promising treatment but are unable to pay for it. They are developing a creative, high-value product candidate portfolio centered on hematology and solid tumors, intending to identify more first-in-class or best-in-class revolutionary therapies. It's all about developing effective treatments that are accessible and cheap to a greater number of patients around the world.

Their approach to cancer biology combines cutting-edge research models and drug discovery methodologies with the scope of a worldwide enterprise. BeiGene is primarily interested in immuno-oncology, which is a key component of cancer treatment. There is enormous potential for cancer immunotherapies to be combined in synergistic ways, as well as for cancer immunotherapies to be combined with other medicines.

BeiGene has developed a wide range of unique in vitro, ex vivo, and in vivo cancer models to assist us in better-selecting targets and screening and evaluating compounds that may have substantial promise, either alone or in combination. To design new cancer models, it is critical that our discovery engine considers tumor-immune system interactions and primary tumor biopsies. Their cancer models, which incorporate aspects of the human immune system, allow them to test possible drug candidates in situations that simulate cancer throughout therapy. This is especially important when drug research is based on assessing different combinations and regimens that target specific mutations while immobilizing cancer cells' defenses.

Founded: 2010 in Beijing, China

Founder: Xiaodong Wang, John V. Oyler

Headquarters: Beijing, China

Website: https://www.beigene.com/

WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions that enable partners to find, develop, and manufacture biologics from idea to commercialization for the benefit of patients all over the world.

WuXi Biologics began developing the capabilities and facilities required for biologics research, development, and GMP manufacture in 2010. In June 2017, WuXi Biologics went public on the Hong Kong Stock Exchange. WuXi Biologics will have 18 manufacturing facilities by 2021, including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. WuXi Biologics was chosen to be a component of the Hong Kong Hang Seng Index in August 2020.

WuXi Biologics leverages its technologies and skills to provide customers with efficient and cost-effective biologics discovery, development, and manufacturing solutions in China, the United States, Ireland, Germany, and Singapore. WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing, as of December 31, 2022.

Environmental, Social, and Governance (ESG) obligations are a fundamental part of WuXi Biologics' ethos and business strategy, and the company aspires to be an ESG leader in the biologics CRDMO sector. Their facilities make use of cutting-edge biomanufacturing technologies and clean energy sources. They have also formed an ESG committee, led by their CEO, to guide the overall ESG strategy and its implementation, thereby strengthening their commitment to sustainability.

Founded: 2015 in Wu Xi City, China

Headquarters: Primary: 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092

Key people: Zhisheng (Chris) Chen (Chief executive officer), Jijie Gu (Chief scientific officer, Executive Vice President), Weichang Zhou (Chief technology officer, Executive Vice President), Christine Lu-Wong (Chief financial officer, Executive Vice President)

Website: https://www.wuxibiologics.com/

The Otsuka group operates in accordance with its long-standing business philosophy, "Otsuka-people creating new products for better health worldwide." The fundamental methodologies for developing new value are Ryukan-godo (they recognize the way by sweating), Jissho (actualization), and Sozosei (creativity). Employees see these as Otsuka's legacy, permeating its daily business activities and aiding in the development of its corporate culture.

The Otsuka group's operations as a whole healthcare organization include daily health maintenance and improvement, as well as disease diagnosis and treatment. The Otsuka Group contributes to global health by developing breakthrough solutions in its Pharmaceutical and Nutraceutical businesses to address unmet medical requirements and unimagined demands.

Otsuka's strengths come from people. Since Otsuka's founding in 1921, personnel around the world have pursued business guided by their enduring company philosophy in order to deliver health to people all around the world. These employees' determination has resulted in the development of numerous strengths.

Otsuka Pharmaceutical's products include:

• CalorieMate
• Pocari Sweat
• Oronamin C
• Aripiprazole / Abilify

Founded: 1921 (Originally founded), 1964 (Current corporation)

Founder: Busaburo Otsuka

Headquarters: Chiyoda, Tokyo, Japan

Website: https://www.otsuka.com/en/

Celltrion, a significant force in the Korean pharmaceutical business, did the unthinkable by launching the world's first "antibody biosimilar" from a country with a relatively underdeveloped pharmaceutical sector. The company has successfully pioneered various unexplored areas, and it expects to continue its expansion as a global biopharmaceutical company with unique methods for small molecule medications and new companies such as the Ubiquitous healthcare platform business.

Celltrion hopes to become a global pharmaceutical firm that promotes health and welfare for all by developing next-generation biopharmaceutical and small-molecule pharmaceutical products.

Celltrion made history by introducing Remsima, the world's first antibody biosimilar, to the market. Remsima offers a larger range of therapy alternatives to more patients than ever before at a low cost. Remsima's effectiveness and safety have been demonstrated by the cumulative number of prescriptions and the results of long-term clinical trials, making it the world's first biosimilar medication trusted by pharmaceutical authorities and patients worldwide.

Celltrion has secured nine pipelines for biosimilar pharmaceuticals used to treat autoimmune disorders. They created the Humira biosimilar CT-P17 in a high-concentration formulation for the global market, estimated to be worth KRW 25 trillion. CT-P17 has a competitive advantage over its competitors due to its high concentration.

Founded: 2002

Founder: Seo Jung-jin

Headquarters: Yeonsu-gu, Incheon, South Korea

Key people: Seo Jung-jin, Chairman, Kee Woo-sung, CEO

Website: https://www.celltrion.com/